In addition to immunomodulatory and cytokine-modulatory properties, @entity2816 has antiangiogenic activity. It has been investigated in a number of @entity5 including @entity1582 , @entity2590 , @entity11 , @entity2826 , @entity1358 , @entity0 , and @entity694 . Its role has been best explored in @entity1582 , where, at daily doses of 100 to 800 mg, it is remarkably active, causing clinically meaningful responses in one-third of extensively pretreated @entity1 and in over half of @entity1 treated early in the course of the disease. It also acts synergistically with corticosteroids and chemotherapy in @entity1582 . @entity2816 produces improvement of cytopenias characteristic of @entity2590 , resulting in the reduction or elimination of transfusion dependence in some @entity1 . Responses have also been seen in one-third of @entity1 with @entity2826 , in a small proportion of @entity1 with @entity1358 and high grade @entity11 and, in combination with @entity2600 , in some @entity1 with @entity694 . @entity2816 is being investigated currently in a number of clinical trials for @entity5 . Drowsiness, @entity1142 and @entity1295 are common adverse effects seen in 75% of @entity1 . Symptoms of @entity1897 and @entity1910 are seen in 30%. A minority of @entity1 experience @entity1168 and @entity715 phenomena. Despite the high frequency of adverse effects, those severe enough to necessitate cessation of therapy are seen in only 10 to 15% of @entity1 . A therapeutic trial of @entity2816 should be considered in all @entity1 with @entity1582 who are unresponsive to or relapse after standard therapy. In other @entity5 , the most appropriate way to use the drug is in the setting of well designed clinical trials. In the absence of access to such studies, @entity2816 could be considered singly or in combination with standard therapy in @entity1 with no meaningful therapeutic options.

@entity2816 in XXXX : potential uses and limitations.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity2826 :: ('MESH:D012514', 'Disease') :: ["Kaposi's sarcoma"] @entity2600 :: ('MESH:C051890', 'Chemical') :: ['irinotecan'] @entity0 :: ('MESH:D001943', 'Disease') :: ['advanced breast cancer'] @entity1910 :: ('MESH:D005076', 'Disease') :: ['skin rash'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancers', 'cancer', 'malignant diseases'] @entity2816 :: ('MESH:D013792', 'Chemical') :: ['thalidomide', 'Thalidomide'] @entity2590 :: ('MESH:D009190', 'Disease') :: ['myelodysplastic syndrome', 'myelodysplastic syndromes'] @entity1295 :: ('MESH:D005221', 'Disease') :: ['fatigue'] @entity1582 :: ('MESH:D009101', 'Disease') :: ['multiple myeloma', 'myeloma'] @entity11 :: ('MESH:D005910', 'Disease') :: ['gliomas', 'glioma'] @entity1358 :: ('MESH:D002292', 'Disease') :: ['renal cell carcinoma'] @entity1897 :: ('MESH:D010523', 'Disease') :: ['peripheral neuropathy'] @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombotic'] @entity1142 :: ('MESH:D003248', 'Disease') :: ['constipation'] @entity694 :: ('MESH:D003110', 'Disease') :: ['colon cancer'] @entity1168 :: ('MESH:D001919', 'Disease') :: ['bradycardia']
@entity5 :: (MESH:D009369,Disease) :: ['cancer']
